CD molecules | Other protein targets | IUPHAR/BPS Guide to PHARMACOLOGY

CD molecules C

Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).

GtoImmuPdb view: OFF

Overview

Show »« Hide

Cluster of differentiation refers to an attempt to catalogue systematically a series of over 300 cell-surface proteins associated with immunotyping. Many members of the group have identified functions as enzymes (for example, see CD73 ecto-5'-nucleotidase) or receptors (for example, see CD41 integrin, alpha 2b subunit). Many CDs are targeted for therapeutic gain using antibodies for the treatment of proliferative disorders. A full listing of all the Clusters of Differentiation proteins is not possible in the Guide to PHARMACOLOGY; listed herein are selected members of the family targeted for therapeutic gain.

Targets

CD2 C Show summary »« Hide summary More detailed page

CD3e C Show summary »« Hide summary More detailed page

CD6 C Show summary »« Hide summary More detailed page

CD19 Show summary »« Hide summary More detailed page

CD20 (membrane-spanning 4-domains, subfamily A, member 1) C Show summary »« Hide summary More detailed page

SIGLEC-2 (CD22) Show summary »« Hide summary More detailed page

Target Id	2786
Nomenclature	CD22
Common abbreviation	SIGLEC-2
Previous and unofficial names	sialic acid binding Ig-like lectin 2 \| SIGLEC-2 \| B-lymphocyte cell adhesion molecule
Genes	CD22 (Hs)
Ensembl ID	ENSG00000012124 (Hs)
UniProtKB AC	P20273 (Hs)

CD28 Show summary »« Hide summary More detailed page

Target Id

2863

Nomenclature

CD28

Previous and unofficial names

cluster of differentiation 28 | CD28 antigen (Tp44)

Genes

CD28 (Hs), Cd28 (Mm), Cd28 (Rn)

Ensembl ID

ENSG00000178562 (Hs), ENSMUSG00000026012 (Mm), ENSRNOG00000010283 (Rn)

UniProtKB AC

P10747 (Hs), P31041 (Mm), P31042 (Rn)

Antibodies

lulizumab pegol (Binding) pK_d 9.3 – 9.4 [28]

Comment

CD28 is expressed on the surface of T cells and is required for the co-stimulaory signal essential for the activation and survival of T cells. CD28 acts in concert with the T cell receptor to stimulate cytokine release. The B7 proteins CD80 and CD86 on the surface of antigen presenting cells bind CD28.
As a drug target, CD28 modulation is being investigated as a treatment for autoimmume conditions.

SIGLEC-3 (CD33) C Show summary »« Hide summary More detailed page

CD38 Show summary »« Hide summary More detailed page

CD52 C Show summary »« Hide summary More detailed page

NCAM1 (neural cell adhesion molecule 1 (CD56)) Show summary »« Hide summary More detailed page

CD66e (CEACAM5) Show summary »« Hide summary More detailed page

Target Id

2836

Nomenclature

CD66e (CEACAM5)

Previous and unofficial names

CEA | carcinoembryonic antigen-related cell adhesion molecule 5

Genes

CEACAM5 (Hs)

Ensembl ID

ENSG0000010538 (Hs)

UniProtKB AC

P06731 (Hs)

Antibodies

labetuzumab (Binding)

labetuzumab govitecan (Binding)

CD74 Show summary »« Hide summary More detailed page

Target Id	2840
Nomenclature	CD74
Previous and unofficial names	HLA-DR-gamma \| Ia-associated invariant chain \| invariant polypeptide of major histocompatibility complex, class II antigen-associated \| CD74 molecule, major histocompatibility complex, class II invariant chain \| Cd74 molecule, major histocompatibility complex, class II invariant chain
Genes	CD74 (Hs), Cd74 (Mm), Cd74 (Rn)
Ensembl ID	ENSG00000019582 (Hs), ENSMUSG00000024610 (Mm), ENSRNOG00000018735 (Rn)
UniProtKB AC	P04233 (Hs), P04441 (Mm), P10247 (Rn)
Comment	CD74 is expressed by many patient-derived multiple myeloma specimens and cell lines [4], making CD74 a promising target for therapeutic intervention in B cell malignancies.

CD79B Show summary »« Hide summary More detailed page

Target Id	2852
Nomenclature	CD79B
Previous and unofficial names	immunoglobulin-associated beta \| IGB \| CD79b molecule, immunoglobulin-associated beta \| Cd79b molecule, immunoglobulin-associated beta
Genes	CD79B (Hs), Cd79b (Mm), Cd79b (Rn)
Ensembl ID	ENSG00000007312 (Hs), ENSMUSG00000040592 (Mm), ENSRNOG00000011917 (Rn)
UniProtKB AC	P40259 (Hs), P15530 (Mm)
Comment	CD79B is a component of the multimeric B lymphocyte antigen receptor (along with CD79A and a membrane-bound antibody that acts as the antigen recognition moiety).

CD80 C Show summary »« Hide summary More detailed page

LILRA4 (CD85g) Show summary »« Hide summary More detailed page

Target Id	2896
Nomenclature	LILRA4 (CD85g)
Previous and unofficial names	leucocyte Ig-like receptor A4 \| ILT7 \| immunoglobulin-like transcript 7
Genes	LILRA4 (Hs)
Ensembl ID	ENSG00000239961 (Hs)
UniProtKB AC	P59901 (Hs)

CD86 C Show summary »« Hide summary More detailed page

semaphorin 4D (CD100) Show summary »« Hide summary More detailed page

Target Id	2883
Nomenclature	semaphorin 4D (CD100)
Previous and unofficial names	SEMAJ \| M-sema-G \| sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D
Genes	SEMA4D (Hs), Sema4d (Mm), Sema4d (Rn)
Ensembl ID	ENSG00000187764 (Hs), ENSMUSG00000021451 (Mm)
UniProtKB AC	Q92854 (Hs), O09126 (Mm)
Comment	Semaphorin 4D is a member of a family of soluble and membrane-bound proteins, originally defined as axonal-guidance factors [9]. A soluble form of the protein (sSEMA4D) is generated by proteolytic cleavage of the extracellular domain [31]. Semaphorin 4D is prediminantly expressed on human leukocytes and plays a functional role in the immune system [13,29].

endoglin (CD105) Show summary »« Hide summary More detailed page

CTLA-4 (cytotoxic T-lymphocyte-associated protein 4 (CD152)) C Show summary »« Hide summary More detailed page

Target Id

2743

Nomenclature

cytotoxic T-lymphocyte-associated protein 4 (CD152)

Common abbreviation

CTLA-4

Previous and unofficial names

ICOS | cytotoxic T-lymphocyte-associated protein 4

Genes

CTLA4 (Hs), Ctla4 (Mm), Ctla4 (Rn)

Ensembl ID

ENSG00000163599 (Hs), ENSMUSG00000026011 (Mm), ENSRNOG00000010336 (Rn)

UniProtKB AC

P16410 (Hs), P09793 (Mm)

Antibodies

ipilimumab (Binding) pK_d >9.0 [12]

tremelimumab (Binding) pK_d 8.9 [15]

NKG2A (CD159a) Show summary »« Hide summary More detailed page

Target Id	2849
Nomenclature	CD159a
Common abbreviation	NKG2A
Previous and unofficial names	killer cell lectin-like receptor subfamily C, member 1 \| NKG2-1/B activating NK receptor \| NKG2-A
Genes	KLRC1 (Hs), Klrc1 (Mm), Klrc1 (Rn)
Ensembl ID	ENSG00000134545 (Hs), ENSMUSG00000030167 (Mm)
UniProtKB AC	P26715 (Hs)

LAG3 (CD223) / CD223 Show summary »« Hide summary More detailed page

Target Id	2932
Nomenclature	LAG3 (CD223)
Systematic nomenclature	CD223
Genes	LAG3 (Hs), Lag3 (Mm), Lag3 (Rn)
Ensembl ID	ENSG00000089692 (Hs), ENSMUSG00000030124 (Mm), ENSRNOG00000021334 (Rn)
UniProtKB AC	P18627 (Hs), Q61790 (Mm)
Comment	LAG3 is a negative regulator of T cells (a check point immunomodulator). It is evolutionarily related to CD4 and both proteins share conserved structual motifs, despite only being ~20% homologous at the amino acid level. Divergent biological functions likely reside in their cytoplasmic domains which contain unique structural and molecular differences.

PD-L1 (programmed cell death 1 ligand 1 (CD274)) Show summary »« Hide summary More detailed page

PD-1 (programmed cell death 1 (CD279)) C Show summary »« Hide summary More detailed page

Target Id

2760

Nomenclature

programmed cell death 1 (CD279)

Common abbreviation

PD-1

Previous and unofficial names

SLEB2

Genes

PDCD1 (Hs), Pdcd1 (Mm), Pdcd1 (Rn)

Ensembl ID

ENSG00000188389 (Hs), ENSMUSG00000026285 (Mm), ENSRNOG00000019043 (Rn)

UniProtKB AC

Q15116 (Hs), Q02242 (Mm)

Antibodies

pembrolizumab (Binding) pK_d ~10.0 [6]

nivolumab (Binding) pK_d 9.1 [14,17-18]

Comment

The endogenous ligands for human PD-1 are programmed cell death 1 ligand 1 (PD-L1 aka CD274 (CD274, Q9NZQ7)) and programmed cell death 1 ligand 2 (PD-L2; PDCD1LG2). These ligands are cell surface peptides, normally involved in immune system regulation. Expression of PD-1 by cancer cells induces immune tolerance and evasion of immune system attack. Anti-PD-1 monoclonal antibodies are used to induce immune checkpoint blockade as a therapeutic intervention in cancer, effectively re-establishing immune vigilance. Pembrolizumab was the first anti-PD-1 antibody to be approved by the US FDA.

CD300a C Show summary »« Hide summary More detailed page

CS1 (CD319) Show summary »« Hide summary More detailed page

Target Id	2850
Nomenclature	CS1 (CD319)
Previous and unofficial names	CRACC \| CS1-L \| CD2-like receptor-activating cytotoxic cells
Genes	SLAMF7 (Hs), Slamf7 (Mm), Slamf7 (Rn)
Ensembl ID	ENSG00000026751 (Hs), ENSMUSG00000038179 (Mm), ENSRNOG00000023209 (Rn)
UniProtKB AC	Q9NQ25 (Hs), Q8BHK6 (Mm)
Comment	CS1 is a member of the signalling lymphocyte activation molecule (SLAM) receptor family. CS1 is a membrane glycoprotein primarily expressed on plasma cells. Homophilic interaction (ie interaction with itself) of CS1 induces B cell proliferation and autocrine cytokine secretion, thus playing a role in various immune functions.

References

Show »« Hide

1. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA et al.. (2011) Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood, 117 (17): 4519-29. [PMID:21378274]

2. Bernstein ID. (2000) Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia, 14 (3): 474-5. [PMID:10720144]

3. Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H. (1993) The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol., 23 (2): 403-11. [PMID:8436176]

4. Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, Goldenberg DM. (2004) CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin. Cancer Res., 10 (19): 6606-11. [PMID:15475450]

5. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. (1992) Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res., 52 (24): 6761-7. [PMID:1458463]

6. Carven GJ, Van Eenennaam H, Dulos GJ. (2010) Antibodies to human programmed death receptor PD-1. Patent number: US20100266617. Assignee: Organon NV. Priority date: 13/06/2008. Publication date: 21/10/2010.

7. da Silva AJ, Brickelmaier M, Majeau GR, Li Z, Su L, Hsu YM, Hochman PS. (2002) Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J. Immunol., 168 (9): 4462-71. [PMID:11970990]

8. De Weers M, Graus Y, Oprins J, Parren P, Van De Winkel J, Van Vugt M. (2010) Antibodies Against Cd38 For Treatment Of Multiple Myeloma. Patent number: US7829673. Assignee: Genmab A/S. Priority date: 23/03/2005. Publication date: 09/11/2010.

9. Giger RJ, Hollis 2nd ER, Tuszynski MH. (2010) Guidance molecules in axon regeneration. Cold Spring Harb Perspect Biol, 2 (7): a001867. [PMID:20519341]

10. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D. (1998) Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res., 22 (2): 185-91. [PMID:9593475]

11. Goldstein G. (1987) Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation. Transplant. Proc., 19 (2 Suppl 1): 1-6. [PMID:3105134]

12. Halk EL, Korman AJ, Lonberg N. (2001) Human ctla-4 antibodies and their uses. Patent number: WO2001014424. Assignee: Medarex Inc. Priority date: 24/08/1999. Publication date: 01/03/2001.

13. Hall KT, Boumsell L, Schultze JL, Boussiotis VA, Dorfman DM, Cardoso AA, Bensussan A, Nadler LM, Freeman GJ. (1996) Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. Proc. Natl. Acad. Sci. U.S.A., 93 (21): 11780-5. [PMID:8876214]

14. Hall RD, Gray JE, Chiappori AA. (2013) Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control, 20 (1): 22-31. [PMID:23302904]

15. Hanson DC, Neveu MJ, Mueller EE, Hanke JH, Gilman SC, Davis CG, Corvalan JR. (2004) Human monoclonal antibodies to CTLA-4. Patent number: US6682736 B1. Assignee: Abgenix, Inc., Pfizer Inc.. Priority date: 22/12/1998. Publication date: 27/01/2004.

16. Irving B, Chiu H, Maecker H, Mariathasan S, Lehar SM, Wu Y, Cheung J. (2012) Anti-PD-L1 antibodies, compositions and articles of manufacture. Patent number: US8217149. Assignee: Genentech, Inc.. Priority date: 09/12/2008. Publication date: 10/07/2012.

17. Kline J, Gajewski TF. (2010) Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs, 11 (12): 1354-9. [PMID:21154117]

18. Korman AJ, Srinivasan M, Wang C, Selby MJ, Chen B, Cardarelli JM. (2006) Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics. Patent number: WO2006121168. Assignee: Ono Pharmaceutical Co. Priority date: 09/05/2005. Publication date: 02/03/2015.

19. Latek R, Fleener C, Lamian V, Kulbokas 3rd E, Davis PM, Suchard SJ, Curran M, Vincenti F, Townsend R. (2009) Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation, 87 (6): 926-33. [PMID:19300198]

20. Linke R, Klein A, Seimetz D. (2010) Catumaxomab: clinical development and future directions. MAbs, 2 (2): 129-36. [PMID:20190561]

21. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med., 174 (3): 561-9. [PMID:1714933]

22. Liu Q. (2013) Fully human antibodies against human cd20. Patent number: WO2013007052. Assignee: Qingfa Liu. Priority date: 13/07/2011. Publication date: 17/01/2013.

23. Mitchell P. (2002) First biotech drug to treat psoriasis. Nat. Biotechnol., 20 (7): 640-1. [PMID:12089534]

24. Nastri HG, Iffland C, Leger O, An Q, Cartwright M, Mckenna SD, Sood VD, Hao G. (2013) Anti-pd-l1 antibodies and uses thereof. Patent number: WO2013079174 A1. Assignee: Merck Patent Gmbh. Priority date: 28/11/2011. Publication date: 06/06/2013.

25. Reslan L, Dalle S, Herveau S, Perrial E, Dumontet C. (2013) Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. Leuk. Lymphoma, [Epub ahead of print]. [PMID:23537278]

26. Shitara K, Niwa R, Natsume A. (2011) Recombinant antibody composition. Patent number: US7923538 B2. Assignee: Kyowa Hakko Kirin Co., Ltd. Priority date: 22/07/2005. Publication date: 12/04/2011.

27. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM. (2004) Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin. Cancer Res., 10 (8): 2868-78. [PMID:15102696]

28. Suchard SJ, Davis PM, Kansal S, Stetsko DK, Brosius R, Tamura J, Schneeweis L, Bryson J, Salcedo T, Wang H et al.. (2013) A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety. J. Immunol., 191 (9): 4599-610. [PMID:24081989]

29. Suzuki K, Kumanogoh A, Kikutani H. (2008) Semaphorins and their receptors in immune cell interactions. Nat. Immunol., 9 (1): 17-23. [PMID:18087252]

30. Vicente Rabaneda EF, Herrero-Beaumont G, Castañeda S. (2013) Update on the use of abatacept for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol, 9 (7): 599-621. [PMID:23899231]

31. Zhu L, Bergmeier W, Wu J, Jiang H, Stalker TJ, Cieslak M, Fan R, Boumsell L, Kumanogoh A, Kikutani H et al.. (2007) Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc. Natl. Acad. Sci. U.S.A., 104 (5): 1621-6. [PMID:17244710]

How to cite this family page

Database page citation:

CD molecules. Accessed on 12/07/2017. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=852.

Concise Guide to PHARMACOLOGY citation:

Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Buneman OP, Catterall WA, Cidlowski JA, Davenport AP, Fabbro D, Fan G, McGrath JC, Spedding M, Davies JA and CGTP Collaborators (2015) The Concise Guide to PHARMACOLOGY 2015/16: Overview. Br J Pharmacol. 172: 5729-5743.